 |
Email:
|
martina.cizmarikova@upjs.sk |
|
Homepage:
|
https://www.upjs.sk/LF/zamestnanec/martina.cizmarikova | |
|
Faculty:
|
LF UPJŠ
-
Pavol Jozef Šafárik University in Košice Faculty of Medicine
|
|
|
Department:
|
UFR
-
Department of Pharmacology
|
|
|
Office:
|
MA3O12 | |
|
Phone:
|
+421 55 234 3252 | |
|
ORCID ID:
|
0000-0002-1158-6161 |
|
Overview of the responsibility for
the delivery, development and quality assurance of the study programme or its part
at the university in the current academic year
|
|
Study programme: Medical Pharmacology - member of jury for defence of PgD; co-guarant of doctoral study program medical pharmacology, study field: Pharmacy, III. degree
|
|
Profile courses
|
|
Pharmacology 2 - General Medicine, I.+II. degree
|
|
Pharmacology 2 - Dentistry, Dental Medicine, I.+II. degree
|
|
Pharmacology - Medical Pharmacology, III. degree
|
|
Selected publications
|
|
ADC: *Vancova Z, *Cizmarikova M, Dragasek J, Zofcakova S, Kolarcik P, Mojzis J: Does G2677T polymorphism of the MDR1 gene make a difference in the therapeutic response to paroxetine in depressed patients in a Slovakian population? Medical Science Monitor, 2018, 24, 3136-3145, IF=1,980, Q2, Cited 2-times; *These authors contributed equally to this work. |
|
ADC: Cizmarikova M: The efficacy and toxicity of using the lingzhi or reishi medicinal mushroom, Ganoderma lucidum (Agaricomycetes), and its products in chemotherapy (review). International Journal of Medicinal Mushrooms, 2017, 19, 861-877, IF=1,852, Q3, Cited 13-times |
|
ADC: Cizmarikova M , Takac P, Spengler G, Kincses A, Nove M, Vilkova M, Mojzis J: New Chalcone derivative inhibits ABCB1 in multidrug resistant T-cell lymphoma and colon adenocarcinoma cells. Anticancer Research: international journal of cancer research and treatment, 2019, 39, 6499-6505, IF: 1,994, Q2, Cited 2-times |
|
ADD: *Bednarova A, *Cizmarikova M, Habalova V, Jarcuskova D: Evaluation of 5-HTTLPR (insertion/deletion) and BDNF (rs6265) genetic variations in the Slovakian individuals suffering from affective disorders. General physiology and biophysics, 2021, 40, 365-376, IF: 1,512, Q3, Cited 0-times; *These authors contributed equally to this work. |
|
Selected projects
|
|
MZ SR 2019/29-UPJŠ-1: Monitoring of selected gene variants and proteomic markers in patients with mental disorders as a contribution to personalized treatment (DepDemGen). 2019-2022, scientific co-worker, principal investigator: doc. MUDr. Miriam Kozárová, PhD. |
|
VEGA 1/0446/22: The study of chalcones in the context of their action on membrane transporters responsible for drug resistance. 2022-2025: principal investigator: doc. MUDr. Martina Čižmáriková, PhD. |
|
International mobilities and visits
|
|
Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland, 25th June - 29th June 2018, Erasmus+, research mobility
|
|
Department of Medical Microbiology and Immunobiology, Szeged, Hungary, 2nd September - 8th September 2018, Mobility to carry out research experiments
|
|
Organisational activities
|
|
Member of the Board of Medical Pharmacology Study Programme for the third degree of
higher education - Faculty of Medicine at Pavol Jozef Šafarik University in Košice, 2021-until now
|
|
Member of the Board of Habilitation Procedure and Inaugural Procedure of Pharmacy
Study Field (ROHIK) - Faculty of Medicine at Pavol Jozef Šafarik University in Košice, 2021-until now
|
|
Member of the commission for the state exams in the field of Pediatrics in General
Medicine Study Programme - Faculty of Medicine at Pavol Jozef Šafarik University in Košice, 2019-until now
|
|
Member of the commission for state exams in the field of Diploma Thesis and Diploma
Thesis Defence in General Medicine Programme - Faculty of Medicine at Pavol Jozef Šafarik University in Košice, 2020-until now
|
|
Supervisor for student science works Pavol Hirjak, Terézia Vlčáková - 3rd place (Medical
Faculty, UPJŠ in Košice) - UPJŠ in Košice, Faculty of Medicine, 2013-2014
|
|
Awards
|
|
Rector´s Award for excellent study results during studies at Faculty of Medicine of UPJŠ in Košice (2001); 4th awarded place in the national competition organized by the Cancer Research Foundation for Young Researchers in category of PhD students (2008); Vladimír Novotný Award for the best original scientific publication in 2012 in the journal Psychiatria pre prax (co-author); the 1st author of the publication awarded among the three best publications at the Faculty of Medicine of UPJŠ in Košice in 2015
|
|
Projects
|
|
MZ SR 2005/46-VOUKE-01: Influence of polymorphisms, expression or activity of selected genes and their products on the therapeutic response in patients with colorectal and mammary carcinoma (2005-2008, scientific co-worker); VEGA 1/0388/08: Study of resistance mechanisms of breast carcinoma at all levels of cells with respect to improve therapy and prognosis of disease (2008-2010, scientific co-worker); VEGA 1/0715/11: Molecular genetic diagnosis of nephrotic syndrome in children (2011-2013, scientific co-worker); VEGA 1/0925/11: Study of genetic polymorphisms and expression of proteins in association with prognosis and therapy of renal adenocarcinoma and nephroblastoma (2011-2013, scientific co-worker); VEGA 1/0224/12: Analysis of expression of drug resistance proteins and their polymorphisms in relation to prognosis and therapy of lung cancer (2012-2014, scientific co-worker); MZ 2019/29-UPJŠ-1: Monitoring of selected gene variants and proteomic markers in patients with mental disorders as a contribution to personalized treatment. (2019-2022, scientific co-worker); VVGS 5/10-11: Association between selected genetic polymorphisms of the MDR1 gene and the therapeutic response to immunosuppressants in pediatric patients with idiopathic nephrotic syndrome (2010-2011, principal investigator); vvgs-2018-904: Innovation in pharmacology education using e-learning educational and testing materials with potential use in the context of blended education (2018-2019, principal grant manager); VEGA 1/0446/22: The study of chalcones in the context of their action on membrane transporters responsible for drug resistance (2022-2025, principal grant manager)
|
